These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

128 related articles for article (PubMed ID: 6249089)

  • 1. Multiple CNS receptor interactions of ergot alkaloids: affinity and intrinsic activity analysis in in vitro binding systems.
    U'Prichard DC
    Adv Biochem Psychopharmacol; 1980; 23():103-15. PubMed ID: 6249089
    [No Abstract]   [Full Text] [Related]  

  • 2. Binding interactions of ergot alkaloids with monoaminergic receptors in the brain.
    Goldstein M; Lew JY; Hata F; Lieberman A
    Gerontology; 1978; 24 Suppl 1():76-85. PubMed ID: 22480
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Autoreceptors in the central nervous system.
    Timmermans PB; Thoolen MJ
    Med Res Rev; 1987; 7(3):307-32. PubMed ID: 3041133
    [No Abstract]   [Full Text] [Related]  

  • 4. Interaction of catecholamine-derived alkaloids with central neurotransmitter receptors.
    Nimit Y; Schulze I; Cashaw JL; Ruchirawat S; Davis VE
    J Neurosci Res; 1983; 10(2):175-89. PubMed ID: 6313954
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Current status of pharmacological receptors in mammalian central nervous system.
    Banerjee PK; Sen AP; Bhattacharya SK
    Indian J Exp Biol; 1989 Apr; 27(4):310-6. PubMed ID: 2553590
    [No Abstract]   [Full Text] [Related]  

  • 6. [Pharmacological basis for the therapeutic use of ergot alkaloids].
    Tran MA; Montastruc JL; Montastruc P
    Presse Med; 1983 Feb; 12(8):517-20. PubMed ID: 6131414
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Interactions of ergot compounds with dopamine receptors and endocrine functions.
    Flückiger E
    J Neural Transm Suppl; 1983; 18():189-204. PubMed ID: 6576114
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Binding studies for serotoninergic, dopaminergic and noradrenergic receptors of Valeriana adscendens Trel. extracts.
    Nencini C; Cavallo F; Capasso A; De Feo V; De Martino L; Bruni G; Giorgi G; Micheli L
    J Ethnopharmacol; 2006 Nov; 108(2):185-7. PubMed ID: 16839726
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Interaction of the novel antipsychotic drug amperozide and its metabolite FG5620 with central nervous system receptors and monoamine uptake sites: relation to behavioral and clinical effects.
    Svartengren J; Pettersson E; Björk A
    Biol Psychiatry; 1997 Aug; 42(4):247-59. PubMed ID: 9270901
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Interactions of Magnolia and Ziziphus extracts with selected central nervous system receptors.
    Koetter U; Barrett M; Lacher S; Abdelrahman A; Dolnick D
    J Ethnopharmacol; 2009 Jul; 124(3):421-5. PubMed ID: 19505549
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Structural modifications of the ergopeptine molecule and their differential influence on the affinities to different receptor binding sites--a structure affinity analysis.
    Closse A; Bolliger G; Dravid A; Frick W; Hauser D; Pfäffli P; Sauter A; Tobler HJ
    Adv Biochem Psychopharmacol; 1983; 36():269-79. PubMed ID: 6305153
    [No Abstract]   [Full Text] [Related]  

  • 12. The affinities of ergot compounds for dopamine agonist and dopamine antagonist receptor sites.
    Goldstein M; Lew JY; Sauter A; Lieberman A
    Adv Biochem Psychopharmacol; 1980; 23():75-82. PubMed ID: 7395625
    [No Abstract]   [Full Text] [Related]  

  • 13. Selective influence of ergot alkaloids on cortical and striatal dopaminergic and sergotonergic receptors.
    Rosenfeld MR; Makman MH; Ahn HS; Thal LJ; Mishra RK; Katzman R
    Adv Biochem Psychopharmacol; 1980; 23():83-93. PubMed ID: 6249092
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Affinity of Iresine herbstii and Brugmansia arborea extracts on different cerebral receptors.
    Nencini C; Cavallo F; Bruni G; Capasso A; De Feo V; De Martino L; Giorgi G; Micheli L
    J Ethnopharmacol; 2006 May; 105(3):352-7. PubMed ID: 16406412
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effect of ergot derivatives on post-decapitation convulsions.
    Hruska RE; Silbergeld EK
    Commun Psychopharmacol; 1980; 4(1):57-62. PubMed ID: 7398243
    [No Abstract]   [Full Text] [Related]  

  • 16. Affinity of cyamemazine metabolites for serotonin, histamine and dopamine receptor subtypes.
    Benyamina A; Arbus C; Nuss P; Garay RP; Neliat G; Hameg A
    Eur J Pharmacol; 2008 Jan; 578(2-3):142-7. PubMed ID: 17936750
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The biologically active conformation of ergot alkaloids.
    Kidric J; Kocjan D; Hadzi D
    Experientia; 1986 Mar; 42(3):327-8. PubMed ID: 3956687
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Multiple neurotransmitter receptors.
    Snyder SH; Goodman RR
    J Neurochem; 1980 Jul; 35(1):5-15. PubMed ID: 6256480
    [No Abstract]   [Full Text] [Related]  

  • 19. Ergot and catecholamine potencies at catecholamine receptors.
    Titeler M; Seeman P
    Adv Biochem Psychopharmacol; 1980; 23():35-40. PubMed ID: 6104912
    [No Abstract]   [Full Text] [Related]  

  • 20. Ziprasidone (CP-88,059): a new antipsychotic with combined dopamine and serotonin receptor antagonist activity.
    Seeger TF; Seymour PA; Schmidt AW; Zorn SH; Schulz DW; Lebel LA; McLean S; Guanowsky V; Howard HR; Lowe JA
    J Pharmacol Exp Ther; 1995 Oct; 275(1):101-13. PubMed ID: 7562537
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.